AnaptysBio (AN6) Financial Statements
AnaptysBio Financial Overview
AnaptysBio's market cap is currently $1.29B. The company's EPS TTM is $6.75; its P/E ratio is 7.15; AnaptysBio has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 234.60M | $ 91.28M | $ 17.16M | $ 10.29M | $ 63.17M |
| Gross Profit | $ 232.18M | $ -72.56M | $ -115.13M | $ -78.51M | $ -35.32M |
| Operating Income | $ 47.90M | $ -114.95M | $ -164.41M | $ -115.15M | $ -56.81M |
| EBITDA | $ 69.25M | $ -92.74M | $ -154.70M | $ -105.26M | $ -55.71M |
| Net Income | $ -13.23M | $ -145.23M | $ -163.62M | $ -128.72M | $ -57.80M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 311.64M | $ 385.37M | $ 390.90M | $ 441.24M | $ 548.10M |
| Total Assets | $ 364.39M | $ 483.83M | $ 452.39M | $ 610.38M | $ 643.07M |
| Total Debt | $ 14.11M | $ 369.46M | $ 17.81M | $ 19.45M | $ 20.95M |
| Net Debt | $ -224.08M | $ 246.38M | $ -18.15M | $ -51.86M | $ -474.77M |
| Total Liabilities | $ 327.19M | $ 412.97M | $ 364.29M | $ 348.28M | $ 286.64M |
| Stockholders' Equity | $ 37.21M | $ 70.87M | $ 88.10M | $ 262.10M | $ 356.43M |
| Cash Flow | |||||
| Free Cash Flow | $ 19.61M | $ -135.69M | $ -121.61M | $ -73.95M | $ -47.29M |
| Operating Cash Flow | $ 19.70M | $ -135.34M | $ -120.80M | $ -73.59M | $ -45.92M |
| Investing Cash Flow | $ 228.03M | $ 95.40M | $ 144.75M | $ -394.85M | $ 38.84M |
| Financing Cash Flow | $ -132.61M | $ 127.05M | $ -59.30M | $ 44.02M | $ 252.30M |
Currency in USD